Healthcare provider profile · identity verified

Jesus Casas, M.D.

Internal Medicine · HOUSTON, TX · NPI 1902008196

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	486	143
Levothyroxine Sodium	Levothyroxine Sodium	304	71
Amlodipine Besylate	Amlodipine Besylate	254	79
Losartan Potassium	Losartan Potassium	251	71
Lisinopril	Lisinopril	226	67
Rosuvastatin Calcium	Rosuvastatin Calcium	205	58
Omeprazole	Omeprazole	190	54
Metoprolol Succinate	Metoprolol Succinate	186	52
Eliquis	Apixaban	162	27
Gabapentin	Gabapentin	157	41
Hydrochlorothiazide	Hydrochlorothiazide	122	37
Pantoprazole Sodium	Pantoprazole Sodium	116	33
Trazodone Hcl	Trazodone Hcl	108	21
Sertraline Hcl	Sertraline Hcl	104	25
Simvastatin	Simvastatin	104	25
Tamsulosin Hcl	Tamsulosin Hcl	100	30
Metformin Hcl	Metformin Hcl	96	29
Albuterol Sulfate Hfa	Albuterol Sulfate	95	35
Furosemide	Furosemide	88	26
Alprazolam	Alprazolam	82	14
Metformin Hcl Er	Metformin Hcl	77	23
Carvedilol	Carvedilol	76	22
Pravastatin Sodium	Pravastatin Sodium	68	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	23
Allopurinol	Allopurinol	64	24
Metoprolol Tartrate	Metoprolol Tartrate	63	18
Clopidogrel	Clopidogrel Bisulfate	62	16
Escitalopram Oxalate	Escitalopram Oxalate	62	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	58	16
Potassium Chloride	Potassium Chloride	55	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	54	11
Tramadol Hcl	Tramadol Hcl	51	14
Fluticasone Propionate	Fluticasone Propionate	50	18
Montelukast Sodium	Montelukast Sodium	50	11
Donepezil Hcl	Donepezil Hcl	49	suppressed
Finasteride	Finasteride	48	14
Zolpidem Tartrate	Zolpidem Tartrate	48	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	47	14
Spironolactone	Spironolactone	47	19
Atenolol	Atenolol	45	11
Fluoxetine Hcl	Fluoxetine Hcl	42	12
Xarelto	Rivaroxaban	41	suppressed
Jardiance	Empagliflozin	38	suppressed
Warfarin Sodium	Warfarin Sodium	38	suppressed
Duloxetine Hcl	Duloxetine Hcl	37	15
Januvia	Sitagliptin Phosphate	37	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	36	suppressed
Mirtazapine	Mirtazapine	36	suppressed
Ropinirole Hcl	Ropinirole Hcl	35	suppressed
Buspirone Hcl	Buspirone Hcl	32	suppressed
Glipizide Er	Glipizide	31	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Famotidine	Famotidine	28	suppressed
Glimepiride	Glimepiride	28	suppressed
Alendronate Sodium	Alendronate Sodium	27	suppressed
Ozempic	Semaglutide	27	suppressed
Valsartan	Valsartan	27	suppressed
Estradiol	Estradiol	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Lorazepam	Lorazepam	24	11
Meloxicam	Meloxicam	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Prednisone	Prednisone	22	12
Spiriva Handihaler	Tiotropium Bromide	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Amiodarone Hcl	Amiodarone Hcl	21	suppressed
Amoxicillin	Amoxicillin	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	20	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	20	suppressed
Baclofen	Baclofen	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Ketoconazole	Ketoconazole	17	13
Lantus	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Sucralfate	Sucralfate	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Perphenazine	Perphenazine	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Azithromycin	Azithromycin	14	13
Bupropion Xl	Bupropion Hcl	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Sulfasalazine	Sulfasalazine	14	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	11
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Celecoxib	Celecoxib	12	suppressed
Cephalexin	Cephalexin	12	12
Fenofibrate	Fenofibrate	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Glipizide	Glipizide	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error